{"id":"W4205173478","doi":"10.2217/fon-2021-1096","title":"A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Enzalutamide; Oncology; Internal medicine; Clinical trial; Cancer; Nivolumab; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001850247,0.002006486,0.002021509,0.0004706626,0.0005845237,0.001362285,0.001069281,0.002259512,0.01012396],"category_scores_gemma":[0.001637846,0.0007293473,0.001776587,0.0005427977,0.001375562,0.001401473,0.0004156049,0.003813041,0.001704914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001200338,"about_ca_system_score_gemma":0.002192958,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001470034,"about_ca_topic_score_gemma":0.00522629,"domain_scores_codex":[0.9993261,0.0003441733,0.00002762191,0.0001313951,0.00005226073,0.0001183544],"domain_scores_gemma":[0.9988949,0.0002084822,0.0002015924,0.00009632146,0.00007742194,0.0005213667],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9545907,0.02089841,0.001017218,0.0003894042,0.0007345037,0.00006777638,0.00008249916,0.0004296893,0.004922209,0.0002237426,0.002653964,0.01398984],"study_design_scores_gemma":[0.9361807,0.06120115,0.001038862,0.00001036267,0.0001188397,0.00003189552,0.00001724452,0.0002345321,0.0002656077,0.0001233952,0.0007682048,0.000009122461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9671072,0.002447207,0.001148893,0.001652423,0.0009003226,0.01505865,0.004853846,0.0003188671,0.006512623],"genre_scores_gemma":[0.9584429,0.001895856,0.003926696,0.003606891,0.0009649604,0.01619295,0.005185696,0.00008140095,0.009702659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01012396,"threshold_uncertainty_score":0.03386807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05788647460081912,"score_gpt":0.3914232047436411,"score_spread":0.333536730142822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}